Synlogic Appoints James Flynn to Board Amidst Director Resignations

An announcement from Synlogic (SYBX) is now available.

Synlogic, Inc. has appointed James Flynn as a new Class I Director to its Board of Directors, with his term expiring at the 2026 annual stockholders’ meeting. Flynn brings a wealth of experience as a healthcare investment specialist, with prior roles at Nerium Capital LLC, ARCA Biopharma, and Amici Capital. Concurrently, directors Mike Burgess, Lisa Kelly-Croswell, and Patricia N. Hurter have resigned, citing no disagreements with the company. Flynn’s appointment is complemented by an incentivizing stock option grant and a standard indemnification agreement.

See more insights into SYBX stock on TipRanks’ Stock Analysis page.